If Canada is to implement national pharmacare, surely we want to know more about the drugs we'll be paying for. To this end, we must tackle a pre-existing challenge: we must open up the evidence our drug regulator houses concerning drug safety and effectiveness. For decades Health Canada has kept that information confidential at the behest of drug manufacturers. This practice limits the ongoing evaluation of a drug's safety and effectiveness and, in turn, provincial and territorial governments' decision-making about which drugs to pay for, not to mention physicians and patients who make decisions about which drugs to prescribe and take.
Matthew Herder is an advisor with EvidenceNetwork.ca and Associate Professor, Health Law Institute, Faculties of Medicine and Law, Dalhousie University, Twitter: @cmrherder
SUBSCRIBE AND FOLLOW
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements. Learn more